Page 44 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $2.82
52wk Low $0.95 Aytu BioPharma, Inc. AYTU $2.00
Denver Corporate Center III
Denver, CO 80237

(USD - in millions) aytubio.com
Market Cap 20.4
Enterprise 16.1
Basic Shares Out. 10.19 COMPANY OVERVIEW
Float 7.04
Institutional Holdings 9.99% Detailed Analysis:Channelchek.com
Short Interest 0.50
Avg. 90-Day Volume 0.18 Aytu is a pharmaceutical company focused on advancing innovative
medicines for complex central nervous system diseases to improve the
quality of life for patients. The Company’s prescription products include
EXXUA (gepirone) extended-release tablets (see Full Prescribing
EPS Data Information, including Boxed WARNING) for the treatment of major
depressive disorder (MDD), Adzenys XR-ODT® (amphetamine)
2022 2023 2024 extended-release orally disintegrating tablets (see Full Prescribing
CQ1 (35.80) (1.93) (0.52) Information, including Boxed WARNING) and Cotempla XR-ODT®
CQ2 (7.00) (0.59) (0.82) (methylphenidate) extended-release orally disintegrating tablets (see
Full Prescribing Information, including Boxed WARNING) for the
CQ3 (1.20) (1.48) (0.15) treatment of attention deficit hyperactivity disorder (ADHD), and a line
CQ4 (2.15) (0.04) 0.13 of legacy products, including Karbinal® ER (carbinoxamine maleate),
CY (46.15) (4.04) (1.36) ® ® Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 2.34
ROE (ttm) -50.23
Debt-to-Total Cap. (mrq) 55.07
Fiscal Year End 30-Jun

Denver Corpo Denver CO 80237

Key Executives
CEO: Disbrow, Joshua
CFO: Selhorn, Ryan
COO: Cabano, Margaret
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures